Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David Delgado is active.

Publication


Featured researches published by David Delgado.


American Journal of Hematology | 2015

Successful Matched Sibling Donor Marrow Transplantation Following Reduced Intensity Conditioning in Children with Hemoglobinopathies

Allison King; Naynesh Kamani; Nancy Bunin; Indira Sahdev; Joel A. Brochstein; Robert J. Hayashi; Michael Grimley; Allistair Abraham; Jacqueline Dioguardi; Ka Wah Chan; Dorothea Douglas; Roberta H. Adams; Martin Andreansky; Eric Jon Anderson; Andrew L. Gilman; Sonali Chaudhury; Lolie Yu; Jignesh Dalal; Gregory A. Hale; Geoff D.E. Cuvelier; Akshat Jain; Jennifer Krajewski; Alfred Gillio; Kimberly A. Kasow; David Delgado; Eric Hanson; Lisa Murray; Shalini Shenoy

Fifty‐two children with symptomatic sickle cell disease sickle cell disease (SCD) (N = 43) or transfusion‐dependent thalassemia (N = 9) received matched sibling donor marrow (46), marrow and cord product (5), or cord blood (1) allografts following reduced intensity conditioning (RIC) with alemtuzumab, fludarabine, and melphalan between March 2003 and May 2014*. The Kaplan–Meier probabilities of overall and event‐free survival at a median of 3.42 (range, 0.75–11.83) years were 94.2% and 92.3% for the group, 93% and 90.7% for SCD, and 100% and 100% for thalassemia, respectively. Treatment‐related mortality (all related to graft versus host disease, GVHD) was noted in three (5.7%) recipients, all 17–18 years of age. Acute and chronic GVHD was noted in 23% and 13%, respectively, with 81% of recipients off immunosuppression by 1 year. Graft rejection was limited to the single umbilical cord blood recipient who had prompt autologous hematopoietic recovery. Fourteen (27%) had mixed chimerism at 1 year and beyond; all had discontinued immunosuppression between 4 and 12 months from transplant with no subsequent consequence on GVHD or rejection. Infectious complications included predominantly bacteremia (48% were staphylococcus) and CMV reactivation (43%) necessitating preemptive therapy. Lymphocyte recovery beyond 6 months was associated with subsidence of infectious complications. All patients who engrafted were transfusion independent; no strokes or pulmonary complications of SCD were noted, and pain symptoms subsided within 6 months posttransplant. These findings support using RIC for patients with hemoglobinopathy undergoing matched sibling marrow transplantation (*www.Clinical Trials.gov: NCT00920972, NCT01050855, NCT02435901). Am. J. Hematol. 90:1093–1098, 2015.


Biology of Blood and Marrow Transplantation | 2017

Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial

Allistair Abraham; Andrew Cluster; David A. Jacobsohn; David Delgado; Monica L. Hulbert; Divyesh Kukadiya; Lisa Murray; Shalini Shenoy

Hematopoietic stem cell transplantation from HLA-matched sibling donors results in disease-free survival of >90% in patients with sickle cell disease (SCD); however, only approximately 18% of these patients have suitable donors available. Unrelated cord blood transplantation (UCBT) is one way to expand donor options for patients with severe SCD, but historically has been associated with high graft rejection rates (50% to 62%). We hypothesized that the addition of thiotepa to a previously tested reduced-intensity conditioning (RIC) regimen would support engraftment after UCBT in patients with SCD. Nine children (age 3 to 10 years) with cerebrovascular complications of SCD underwent 5-6/6 HLA-matched (A, B, and DRB1 loci) UCBT after conditioning with hydroxyurea, alemtuzumab, fludarabine, thiotepa, and melphalan. A calcineurin inhibitor and mycophenolate mofetil were used for graft-versus-host-disease (GVHD) prophylaxis. With median follow up of 2.1 years (range, 1 to 4.2 years), 7 patients had sustained donor cell engraftment and are free of SCD, and 2 patients had autologous recovery. Acute GVHD (grade II-IV) and mild and moderate chronic GVHD developed in 3 patients, 2 patients, and 1 patient, respectively. At >2 years post-UCBT, 4 of 5 patients discontinued systemic immunosuppression. Seven patients had viral infections (cytomegalovirus, Epstein-Barr virus, respiratory syncytial virus, or adenovirus) and recovered. The 1-year overall survival and disease-free survival rates were 100% and 78%, respectively. Thus, this RIC regimen was able to achieve donor engraftment in the majority of patients. Future efforts will focus on further reducing rates of acute GVHD and viral infection.


Pediatric Blood & Cancer | 2016

Alemtuzumab, Fludarabine, Low-Dose TBI, and Double Umbilical Cord Transplant for Primary Graft Failure in a Patient with Recurrent HLH

Kerry Hege; Troy C. Quigg; David Delgado

Graft failure occurs at relatively low frequency, but commonly in hemophagocytic lymphohistiocytosis (HLH), especially with umbilical cord blood transplant (UCBT). No standard approaches to management of graft failure exist. We present a challenging case of relapsed HLH following first UCBT with primary graft failure following second UCBT. We report a novel reduced intensity conditioning regimen of alemtuzumab, 4 Gy total body irradiation and fludarabine for salvage of primary graft failure followed by double UCBT. The reported patient successfully engrafted with 100% donor chimerism following salvage UCBT with no occurrence of acute or chronic graft‐versus‐host disease.


Biology of Blood and Marrow Transplantation | 2018

Unrelated Donor Transplantation in Children with Thalassemia using Reduced-Intensity Conditioning: The URTH Trial

Shalini Shenoy; Mark C. Walters; Alex Ngwube; Sandeep Soni; David A. Jacobsohn; Sonali Chaudhury; Michael Grimley; K. W. Chan; Ann E. Haight; Kimberley A. Kasow; Suhag Parikh; Martin Andreansky; Jim Connelly; David Delgado; Kamar Godder; Gregory A. Hale; Michael L. Nieder; Michael A. Pulsipher; Felicia Trachtenberg; Ellis J. Neufeld; Janet L. Kwiatkowski; Alexis A. Thompson

Allogeneic hematopoietic stem cell transplantation (HSCT) can cure transfusion-dependent thalassemia (TDT). In a multicenter trial we investigated the efficacy of reduced-intensity conditioning (RIC) before unrelated donor (URD) HSCT in children with TDT. Thirty-three children, ages 1 to 17 years, received bone marrow (BM) or umbilical cord blood (UCB) allografts. Median time to neutrophil engraftment was 13 days (range, 10 to 25) and 24 days (range, 18 to 49) and platelet engraftment 23 days (range, 12 to 46) and 50 days (range, 31 to 234) after BM and UCB allografts, respectively. With a median follow-up of 58 months (range, 7 to 79), overall and thalassemia-free survival was 82% (95% CI, .64% to .92%) and 79% (95% CI, .6% to .9%), respectively. The cumulative incidence of grades II to IV acute graft-versus-host disease (GVHD) after BM and UCB allografts was 24% and 44%; the 2-year cumulative incidence of chronic extensive GVHD was 29% and 21%, respectively; 71% of BM and 91% of UCB recipients discontinued systemic immunosuppression by 2 years. Six patients who had Pesaro risk class 2 (n = 5) and class 3 (n = 1) died of GVHD (n = 3), viral pneumonitis (n = 2) and pulmonary hemorrhage (n = 1). Outcomes after this RIC compared favorably with URD HSCT outcomes for TDT and supported engraftment in 32 of 33 patients. Efforts to reduce GVHD and infectious complications are being pursued further.


Biology of Blood and Marrow Transplantation | 2018

Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium

Eneida R. Nemecek; Ralf A. Hilger; Alexia Adams; Bronwen E. Shaw; Deidre M. Kiefer; Jennifer Le-Rademacher; John E. Levine; Gregory A. Yanik; Wing Leung; Julie-An Talano; Paul R. Haut; David Delgado; Neena Kapoor; Aleksandra Petrovic; Roberta H. Adams; Rabi Hanna; Hemalatha G. Rangarajan; Jignesh Dalal; Joseph H. Chewning; Michael R. Verneris; Stacy Epstein; Lauri Burroughs; Evelio Perez-Albuerne Md; Michael A. Pulsipher; Colleen Delaney

This multicenter study evaluated a treosulfan-based regimen in children and young adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplant (HCT). Forty patients with median age 11 years (range, 1 to 19) underwent allogeneic HCT for AML in first (n = 18), second (n = 11), and third or greater remission (n = 3) or MDS (n = 8) using bone marrow (n = 25), peripheral blood stem cells (n = 5), or cord blood (n = 9). The regimen consisted of body surface area (BSA)-based treosulfan 10 g/m2/day (BSA ≤ .5 m2), 12 g/m2/day (BSA > .5 to 1.0 m2), or 14 g/m2/day (BSA > 1.0 m2) on days -6 to -4; fludarabine 30 mg/m2/day on days -6 to -2; and a single fraction of 200 cGy total body irradiation on day -1. Graft-versus-host disease (GVHD) prophylaxis included tacrolimus and methotrexate for marrow and peripheral blood stem cell and cyclosporine/mycophenolate mofetil for cord blood. One-year overall survival, disease-free survival, and nonrelapse mortality were 80%, 73%, and 3%, respectively. One-year relapse was 38% for AML and 13% for MDS. No serious organ toxicities were observed. All 37 assessable patients engrafted. Cumulative incidences of grades II to IV acute GVHD and chronic GVHD were 22% and 40%, respectively. BSA-based treosulfan dosing resulted in predictable area under the curve and maximum concentration, which is required for dosing without measuring individual pharmacokinetic parameters. Observed differences in pharmacokinetics did not impact disease control or regimen toxicity. This BSA-based treosulfan regimen resulted in excellent engraftment and disease-free survival and minimal toxicity and transplant-related mortality (3%) in children and young adults with AML and MDS.


Biology of Blood and Marrow Transplantation | 2017

Risk Factors for Subsequent Central Nervous System Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR)

Melissa Gabriel; Bronwen E. Shaw; Ruta Brazauskas; Min Chen; David A. Margolis; Henrik Sengeløv; Ann Dahlberg; Ibrahim Ahmed; David Delgado; Hillard M. Lazarus; Brenda Gibson; Kasiani C. Myers; Rammurti T. Kamble; Aly Abdel-Mageed; Chi Kong Li; Mary E.D. Flowers; Minoo Battiwalla; Bipin N. Savani; Navneet S. Majhail; Peter J. Shaw

Survivors of hematopoietic cell transplantation (HCT) are at risk of subsequent solid tumors, including central nervous system (CNS) tumors. The risk of CNS tumors after HCT in pediatric HCT recipients is not known. We evaluated the incidence and risk factors for CNS tumors in pediatric recipients of allogeneic HCT reported to the Center for International Blood and Marrow Transplant Research between 1976 and 2008. A case control design was used. There were no CNS tumors in the nonmalignant cohort (n = 4543) or in those undergoing HCT for solid tumors (n = 26). There were 59 CNS tumors in 8720 patients transplanted for hematologic malignancies. In comparison with the general population, pediatric HCT recipients with hematologic malignancies had a 33 times higher than expected rate of CNS tumors (95% confidence interval, 22.98 to 45.77; P < .0001). The cumulative incidence of subsequent CNS tumors was 1.29% (95% confidence interval .87 to 1.87) at 20 years after HCT. Significant risk factors in the entire cohort were having an unrelated donor (HR, 3.35; P = .0002) and CNS disease before HCT for both acute lymphoblastic leukemia (HR, 8.21; P = .0003) and acute myeloid leukemia (HR, 6.21; P = .0174). Analysis of the matched cohort showed having an unrelated donor transplant (HR, 4.79; P = .0037), CNS disease before HCT (HR, 7.67; P = .0064), and radiotherapy exposure before conditioning (HR, 3.7; P = .0234) to be significant risk factors. Chronic graft-versus-host disease was associated with a lower risk (HR, .29; P = .0143). Survivors of HCT for nonmalignant diseases did not show an increased incidence of CNS tumors, whereas survivors of hematologic malignancies have a markedly increased incidence of CNS tumors that warrants lifelong surveillance.


Biology of Blood and Marrow Transplantation | 2017

Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis

Muna Qayed; Tao Wang; Michael T. Hemmer; Stephen Spellman; Mukta Arora; Daniel Couriel; Amin M. Alousi; Joseph Pidala; Hisham Abdel-Azim; Mahmoud Aljurf; Mouhab Ayas; Menachem Bitan; Mitchell S. Cairo; Sung Won Choi; Christopher E. Dandoy; David Delgado; Robert Peter Gale; Gregory A. Hale; Haydar Frangoul; Rammurti T. Kamble; Mohamed A. Kharfan-Dabaja; Leslie Lehman; John E. Levine; Margaret L. MacMillan; David I. Marks; Taiga Nishihori; Richard Olsson; Peiman Hematti; Olov Ringden; Ayman Saad

Relapse remains the major cause of mortality after hematopoietic cell transplantation (HCT) for pediatric acute leukemia. Previous research has suggested that reducing the intensity of calcineurin inhibitor-based graft-versus-host disease (GVHD) prophylaxis may be an effective strategy for abrogating the risk of relapse in pediatric patients undergoing matched sibling donor (MSD) HCT. We reasoned that the benefits of this strategy could be maximized by selectively applying it to those patients least likely to develop GVHD. We conducted a study of risk factors for GVHD, to risk-stratify patients based on age. Patients age <18 years with leukemia who received myeloablative, T cell-replete MSD bone marrow transplantation and calcineurin inhibitor-based GVHD prophylaxis between 2000 and 2013 and were entered into the Center for International Blood and Marrow Transplant Research registry were included. The cumulative incidence of grade II-IV acute GVHD (aGVHD) was 19%, that of grade II-IV aGVHD 7%, and that of chronic GVHD (cGVHD) was 16%. Compared with age 13 to 18 years, age 2 to 12 years was associated with a lower risk of grade II-IV aGVHD (hazard ratio [HR], .42; 95% confidence interval [CI], .26 to .70; P = .0008), grade II-IV aGVHD (HR, .24; 95% CI, .10 to .56; P = .001), and cGVHD (HR, .32; 95% CI, .19 to .54; P < .001). Compared with 2000-2004, the risk of grade II-IV aGVHD was lower in children undergoing transplantation in 2005-2008 (HR, .36; 95% CI, .20 to .65; P = .0007) and in 2009-2013 (HR, .24; 95% CI. .11 to .53; P = .0004). Similarly, the risk of grade III-IV aGVHD was lower in children undergoing transplantation in 2005-2008 (HR, .23; 95% CI, .08 to .65; P = .0056) and 2009-2013 (HR, .16; 95% CI, .04 to .67; P = .0126) compared with those doing so in 2000-2004. We conclude that aGVHD rates have decreased significantly over time, and that children age 2 to 12 years are at very low risk for aGVHD and cGVHD. These results should be validated in an independent analysis, because these patients with high-risk malignancies may be good candidates for trials of reduced GVHD prophylaxis.


Biology of Blood and Marrow Transplantation | 2017

Reduced Intensity Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease: Results of a Phase I Trial

Allistair Abraham; Andrew Cluster; David A. Jacobsohn; David Delgado; Monica L. Hulbert; Divyesh Kukadiya; Lisa Murray; Shalini Shenoy


Biology of Blood and Marrow Transplantation | 2018

Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression

David A. Jacobsohn; Michael R. Loken; Mingwei Fei; Alexia Adams; Lisa Eidenschink Brodersen; Brent R. Logan; Kwang Woo Ahn; Bronwen E. Shaw; Morris Kletzel; Marie Olszewski; Sana Khan; Soheil Meshinchi; Amy Keating; Andrew C. Harris; Reggie Duerst; Steven P. Margossian; Paul L. Martin; Aleksandra Petrovic; Christopher C. Dvorak; Eneida R. Nemecek; Michael Boyer; Allen R. Chen; Jeffrey H. Davis; Shalini Shenoy; Sureyya Savasan; Michelle Hudspeth; Roberta H. Adams; Victor Lewis; Albert Kheradpour; Kimberly A. Kasow


PMC | 2017

High-dose sitagliptin for systemic inhibition of dipeptidylpeptidase-4 to enhance engraftment of single cord umbilical cord blood transplantation

Sherif S. Farag; Robert P. Nelson; Mitchell S. Cairo; Heather A. O’Leary; Shuhong Zhang; Carol Huntley; David Delgado; Jennifer E. Schwartz; Mohammad Abu Zaid; Rafat Abonour; Michael J. Robertson; Hal E. Broxmeyer

Collaboration


Dive into the David Delgado's collaboration.

Top Co-Authors

Avatar

Shalini Shenoy

St. Louis Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Allistair Abraham

Children's National Medical Center

View shared research outputs
Top Co-Authors

Avatar

David A. Jacobsohn

Children's National Medical Center

View shared research outputs
Top Co-Authors

Avatar

Lisa Murray

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Michael A. Pulsipher

Children's Hospital Los Angeles

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andrew Cluster

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Divyesh Kukadiya

Children's National Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge